MedPath
FDA Approval

Lamivudine and Zidovudine

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
July 13, 2023
Labeling Type
Human Prescription Drug Label
Zidovudine(300 mg in 1 1)
Lamivudine(150 mg in 1 1)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Macleods Pharmaceuticals Limited

Macleods Pharmaceuticals Limited

918608365

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Lamivudine and Zidovudine

Product Details

NDC Product Code
33342-003
Application Number
ANDA090679
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
July 13, 2023
Code: 4B9XT59T7SClass: ACTIBQuantity: 300 mg in 1 1
Code: 2T8Q726O95Class: ACTIBQuantity: 150 mg in 1 1
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2Class: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61UClass: IACT
POLYSORBATE 80Inactive
Code: 6OZP39ZG8HClass: IACT
POLYETHYLENE GLYCOL, UNSPECIFIEDInactive
Code: 3WJQ0SDW1AClass: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JPClass: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT
HYPROMELLOSESInactive
Code: 3NXW29V3WOClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
© Copyright 2025. All Rights Reserved by MedPath